Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 USD | -0.50% | +5.79% | +1.52% |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
RNA Based Therapeutics
100.0
%
| 4 | 100.0 % | 7 | 100.0 % | +65.99% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 7 | 100.0 % | +65.99% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel de Boer
CEO | Chief Executive Officer | 41 | 12-02-20 |
Founder | 60 | 12-02-20 | |
Jurriaan Dekkers
DFI | Director of Finance/CFO | - | 22-09-30 |
Sheila Sponselee
COO | Chief Operating Officer | - | 20-03-31 |
Sarah Kiely
IRC | Investor Relations Contact | - | 19-09-30 |
Andrew Morris
PRN | Corporate Officer/Principal | - | 18-12-31 |
René Beukema
LAW | General Counsel | 60 | 13-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Domenico Valerio
FOU | Founder | 67 | 12-02-20 |
Founder | 60 | 12-02-20 | |
Alison Lawton
BRD | Director/Board Member | 62 | 14-09-16 |
Bart Filius
BRD | Director/Board Member | 53 | 19-05-20 |
James Shannon
BRD | Director/Board Member | 67 | 16-06-20 |
Theresa Heggie
COO | Chief Operating Officer | 63 | 19-06-30 |
Begoña Carreño
BRD | Director/Board Member | 52 | 22-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 84,248,384 | 66,003,992 ( 78.34 %) | 0 | 78.34 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. |
Pharmaceuticals: Major
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.52% | 164M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- PRQR Stock
- Company ProQR Therapeutics N.V.